We are live on ! Find out more
PHS

PFM Health Sciences Portfolio holdings

AUM $1.1B
1-Year Est. Return 57.92%
This Fund
S&P 500
This Quarter Est. Return
-4.77%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$1.61B
AUM Growth
-$151M
Cap. Flow
-$42.4M
Cap. Flow %
-2.62%
Top 10 Hldgs %
46.28%
Holding
103
New
28
Increased
9
Reduced
25
Closed
20

Top Buys

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$24.3M
2
IJH icon
iShares Core S&P Mid-Cap ETF
IJH
+$22.3M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$20.6M
4
BHVN icon
Biohaven
BHVN
+$20.2M
5
RSP icon
Invesco S&P 500 Equal Weight ETF
RSP
+$19.5M

Top Sells

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$92.8M
2
MRK icon
Merck
MRK
+$61.6M
3
ACHC icon
Acadia Healthcare
ACHC
+$43.5M
4
ELV icon
Elevance Health
ELV
+$29.3M
5
AMGN icon
Amgen
AMGN
+$29.1M

Sector Composition

Rank Sector Weight
1 Healthcare 75.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SWTX
51
CALL
DELISTED
SpringWorks Therapeutics
SWTX
$5.42M 0.34%
+150,000
New +$5.24M
KWEB icon
52
KraneShares CSI China Internet ETF
KWEB
$5.65B
$5.29M 0.33%
+180,974
New +$5.81M
QURE icon
53
uniQure
QURE
$3.03B
$5M 0.31%
283,158
+161,530
+133% +$1.39M
XENE icon
54
Xenon Pharmaceuticals
XENE
$6.2B
$4.59M 0.28%
116,998
-62,880
-35% -$2.6M
ACLX
55
DELISTED
Arcellx
ACLX
$4.34M 0.27%
56,603
-3,999
-7% -$345K
HOWL icon
56
Werewolf Therapeutics
HOWL
$19.5M
$4.3M 0.27%
2,905,465
-493,282
-15% -$1.01M
BNTX icon
57
BioNTech
BNTX
$23.3B
$3.77M 0.23%
+33,109
New +$3.78M
BPMC
58
DELISTED
Blueprint Medicines
BPMC
$3.74M 0.23%
+42,840
New +$3.92M
ITCI
59
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$3.39M 0.21%
40,610
-36,777
-48% -$3.02M
MGX icon
60
Metagenomi Therapeutics
MGX
$45.9M
$3.2M 0.2%
885,803
-148,199
-14% -$358K
PMVP icon
61
PMV Pharmaceuticals
PMVP
$62.9M
$3.14M 0.19%
2,079,245
+68,205
+3% +$108K
INSM icon
62
Insmed
INSM
$21.7B
$3.02M 0.19%
43,774
-108,454
-71% -$7.81M
TGTX icon
63
TG Therapeutics
TGTX
$7.62B
$2.97M 0.18%
98,674
-134,736
-58% -$3.87M
SGMT icon
64
Sagimet Biosciences
SGMT
$534M
$2.92M 0.18%
649,006
– –
SNDX icon
65
Syndax Pharmaceuticals
SNDX
$1.76B
$2.73M 0.17%
206,871
-217,039
-51% -$3.71M
ADAP
66
DELISTED
Adaptimmune Therapeutics
ADAP
$2.62M 0.16%
4,871,969
-5,128,818
-51% -$3.74M
ALKS icon
67
Alkermes
ALKS
$8.33B
$2.32M 0.14%
80,719
-124,354
-61% -$3.58M
JAZZ icon
68
Jazz Pharmaceuticals
JAZZ
$16.3B
$2.17M 0.13%
+17,597
New +$2.07M
IOBT
69
DELISTED
IO Biotech
IOBT
$2.15M 0.13%
2,341,107
– –
INBX icon
70
Inhibrx
INBX
$1.24B
$2.09M 0.13%
135,546
– –
CELC icon
71
Celcuity
CELC
$4.5B
$2.08M 0.13%
158,746
-551,509
-78% -$7.78M
CMPS
72
Compass Pathways
CMPS
$1.79B
$1.71M 0.11%
451,267
– –
KROS icon
73
Keros Therapeutics
KROS
$197M
$1.65M 0.1%
104,323
+3,273
+3% +$170K
BBIO icon
74
CALL
BridgeBio Pharma
BBIO
$16.1B
$1.37M 0.09%
+50,000
New +$1.29M
IOVA icon
75
Iovance Biotherapeutics
IOVA
$1.99B
$978K 0.06%
132,152
– –
1 2
3
4 5

Similar funds

DAM
Delta Asset Management Memphis, Tennessee $1.1B AUM 14.89% 1-Year Est. Return
MAM
Mark Asset Management New York $1.1B AUM 43.79% 1-Year Est. Return
LCM
Legato Capital Management San Francisco, California $1.1B AUM 61.65% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return
MIA
MMBG Investment Advisors Miami, Florida $1.09B AUM 30.96% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return
SL
Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return

PFM Health Sciences's Q4 2024 Portfolio in Review

As of Q4 2024, PFM Health Sciences held 103 positions worth $1.61B, down 8.6% from $1.76B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

PFM Health Sciences's Q4 2024 filing shows 28 new, 9 increased, 25 reduced and 20 closed positions. Its largest new stake was DexCom: 328,763 shares worth $25.6M. The largest sale was Cytokinetics, an estimated $92.8M.

By sector, the portfolio is most concentrated in Healthcare at 75% of assets, down from 96% a quarter earlier.

  • PFM Health Sciences's largest Q4 2024 buy was DexCom: 328,763 shares worth $25.6M.
  • PFM Health Sciences added most to Edwards Lifesciences in Q4 2024, an estimated $14.2M increase.
  • PFM Health Sciences's biggest Q4 2024 reduction was Intuitive Surgical, cutting an estimated $23M.
  • PFM Health Sciences fully exited Cytokinetics in Q4 2024, selling an estimated $92.8M.
  • PFM Health Sciences's ten largest holdings make up 46% of its $1.61B portfolio in Q4 2024.
  • PFM Health Sciences opened 28 new positions and closed 20 in Q4 2024.
  • PFM Health Sciences's portfolio value fell 8.6% quarter-over-quarter to $1.61B.

Based on PFM Health Sciences's 13F filing for Q4 2024, filed 14 Feb 2025.